7 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 7, Terminated 3, Not yet recruiting 1, Recruiting 1 |
Follow Fungal Infection: new trials by email Literature Review of Fungal Infection trials Research Report on Fungal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm Individualization of first voriconazole maintenance doses - Aspergillosis Invasive, Fungal Infection | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 30 | 2024-10-01 | 2024-09-03 |
| Itraconazole Oral Absorption fast itraconazole tablet, medium itraconazole tablet, slow itraconazole tablet - Fungal Infection | Phase 4 | Completed | University of Maryland, Baltimore | 17 | 2020-02-10 | 2023-10-05 |
| Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Posaconazole pharmacokinetics - Posaconazole, Pharmacokinetics | Phase 4 | Recruiting | Melbourne Health | 100 | 2019-08-01 | 2025-02-28 |
| Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis amphotericin B in 30% DMSO, 30% DMSO - Fungal Infection, Onychomycosis | Phase 4 | Completed | Mahidol University | 19 | 2019-01-15 | 2021-09-28 |
| CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels Voriconazole genotype-specific dosing, Standard of Care - Aspergillosis Invasive, Fungal Infection | Phase 4 | Completed | University Health Network, Toronto | 30 | 2018-01-10 | 2020-11-03 |
| A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) Posaconazole, Calogen® - Fungal Infection | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 26 | 2013-01-23 | 2018-10-09 |
| A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Prospective TDM Arm - Fungal Infection | Phase 4 | Completed | Johns Hopkins University | 29 | 2012-01-01 | 2016-08-18 |
| Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Anidulafungin, Liposomal amphotericin B - Liver Disease, Fungal Infection | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 61 | 2011-11-01 | 2014-05-30 |
| Effect of Weight and/or Obesity on Caspofungin Drug Concentrations Caspofungin - Obesity, Fungal Infection | Phase 4 | Completed | Texas Tech University Health Sciences Center | 18 | 2010-02-01 | 2017-02-10 |
| Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Posaconazole - Fungal Infection, Acute Myelogenous Leukemia | Phase 4 | Completed | Merck Sharp & Dohme LLC | 75 | 2007-12-01 | 2017-04-07 |
| ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia liposomal amphotericin B (AmBisome®) - Fungal Infection | Phase 4 | Terminated | Gilead Sciences | 20 | 2006-11-01 | 2007-08-21 |
| Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Posaconazole - Fungal Infection | Phase 4 | Terminated | University of Pittsburgh | 10 | 2004-08-01 | 2008-12-17 |
Mycoses (12) · Hematologic Neoplasms (2) · Invasive Fungal Infections (2) · Candidiasis, Invasive (1) · Leukemia, Myeloid, Acute (1) · Liver Diseases (1) · Neutropenia (1) · Obesity (1) · Onychomycosis (1)
Bacterial Infections and Mycoses (12) · Infections (12) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Site (2) · Agranulocytosis (1) · Body Weight (1) · Candidiasis (1) · Cytopenia (1) · Dermatomycoses (1) · Digestive System Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Leukocyte Disorders (1)
posaconazole (3) · liposomal amphotericin B (2) · Amphotericin B (1) · Anidulafungin (1) · Blood Specimen Collection (1) · Caspofungin (1) · Dimethyl Sulfoxide (1) · Standard of Care (1) · Voriconazole (1)
Merck Sharp & Dohme LLC (2) · Fundacion SEIMC-GESIDA (1) · Gilead Sciences (1) · Johns Hopkins University (1) · Mahidol University (1) · Melbourne Health (1) · Texas Tech University Health Sciences Center (1) · University Health Network, Toronto (1) · University Hospital, Grenoble (1) · University of Maryland, Baltimore (1) · University of Pittsburgh (1)
United States (4) · Australia (1) · Canada (1) · France (1) · Germany (1) · Spain (1) · Thailand (1)
Asuncion Moreno, MD (1) · Carlos Cervera, MD (1) · Catherine Hardalo, MD (1) · Charussri Leeyaphan, MD (1) · Gautier-Veyret Elodie (1) · Kieren Marr, MD (1) · Marisa Battistella, PharmD (1) · Mark Sampson (1) · Ronald Hall, PharmD, MSCS (1) · Sumanas Bunyaratavej, MD (1)
PMID 10233295, PMID 10642676, PMID 14723731, PMID 20347657, PMID 21820203, PMID 22236569, PMID 22290953, PMID 22976905, PMID 23416171, PMID 23459494, PMID 24079583, PMID 25013957, PMID 25639524, PMID 26471716, PMID 27799043, PMID 27815659
5UL1RR024982-02 (1)